STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Stopped early · Phase 2

Conditions studied: Melanoma

In brief

STA9090 is a drug which inactivates or blocks the work of a protein called Heat Shock Protein 90 or HSP90. HSP90 is a protein that helps some molecules inside your cells to have the right shape. By stopping HSP90's activity, those molecules never get to have the right structure of be functional and they are destroyed. The investigators believe that if they stop the activity of HSP90, the rapidly dividing cells that are in your tumor(s) may slow down. In this research study the investigators are looking to see how well STA9090 works in stopping the spread of your melanoma.

Key facts

Study ID
NCT01551693
Run by
Dana-Farber Cancer Institute
People needed
3
Starts
2011-09-01
Expected to finish
2012-09-01
Last updated by the study team
2017-04-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.